What it isReversible P2Y12 antagonist; acute coronary syndrome.
Why this oneIt needs no metabolic activation, so it works in CYP2C19 poor metabolizers where clopidogrel fails, and it acts faster and reverses sooner.
What limits itTwice-daily dosing, more bleeding than clopidogrel, and dyspnea in about one in seven. Aspirin above 100 mg reduces its benefit.
BOXED WARNING Bleeding risk: can cause significant, sometimes fatal bleeding; do not use with active pathological bleeding or history of intracranial hemorrhage; do not start before urgent CABG; stopping increases risk of subsequent CV events.
FDA dosing
Population
Start
Target
Max
ACS or history of MI
Adults
180 mg load, then 90 mg BID x1 year
60 mg BID after 1 year
CAD, no prior stroke or MI
Adults
60 mg BID
60 mg BID
Acute ischemic stroke or TIA
Adults
180 mg load, then 90 mg BID
90 mg BID up to 30 days
Renal No adjustment needed
Hepatic Avoid in severe hepatic impairment; no adjustment in mild; caution in moderate
Instructions
Use with daily aspirin 75-100 mg; avoid aspirin doses above 100 mg
Give first maintenance dose 6-12 hours after loading dose
May crush tablets, mix with water, and drink or give via nasogastric tube
Do not co-administer with another oral P2Y12 inhibitor
If interrupted for surgery, stop 5 days before major-bleeding-risk surgery; resume when hemostasis achieved